Dovonex (calcipotriol) / LEO Pharma, Novartis 
Welcome,         Profile    Billing    Logout  
 10 Diseases   7 Trials   7 Trials   318 News 


«12345
  • ||||||||||  Journal:  Drugs for psoriasis. (Pubmed Central) -  Nov 13, 2019   
    No abstract available
  • ||||||||||  Dovonex (calcipotriol) / Leo Pharma, Novartis
    Journal:  Eosinophils determine dermal thickening and water loss in a MC903 model of atopic dermatitis. (Pubmed Central) -  Sep 14, 2019   
    Indeed, eosinophil depletion significantly ameliorated AD pathology, most notably barrier dysfunction, to a similar extent as blocking of the IL-4/IL-13 axis by genetic deletion of STAT6. Thus, this study has identified eosinophils to be critical for the development and maintenance of AD, thereby proposing these effector cells as therapeutic targets for the treatment of AD.
  • ||||||||||  dexamethasone / generics
    Journal:  Skin inflammation exacerbates food allergy symptoms in epicutaneously sensitized mice. (Pubmed Central) -  Aug 9, 2019   
    Even after eliminating exposure to the antigen, inflammation from skin barrier disruption can exacerbate the severity of food allergy symptoms. Serum baseline mmcp1 levels might be an effective marker for predicting the severity of antigen-induced allergic symptoms.
  • ||||||||||  Journal:  Risankizumab (Skyrizi) for psoriasis. (Pubmed Central) -  Aug 6, 2019   
    Serum baseline mmcp1 levels might be an effective marker for predicting the severity of antigen-induced allergic symptoms. No abstract available
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Trial completion, Trial completion date, Trial primary completion date:  Topical Vitamin D in Acute Graft Versus Host Disease of the Skin (clinicaltrials.gov) -  Jun 12, 2019   
    P=N/A,  N=10, Completed, 
    No abstract available Recruiting --> Completed | Trial completion date: Dec 2020 --> Mar 2019 | Trial primary completion date: Dec 2019 --> Mar 2019
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Trial completion date, Trial primary completion date:  Topical Vitamin D in Acute Graft Versus Host Disease of the Skin (clinicaltrials.gov) -  Feb 11, 2019   
    P=N/A,  N=10, Recruiting, 
    Slow dissolution of calcipotriol crystals in the joint can extend the pharmaceutical impact on the synovium, cartilage and subcortical bone. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Trial completion date, Trial primary completion date:  Topical Vitamin D in Acute Graft Versus Host Disease of the Skin (clinicaltrials.gov) -  Apr 10, 2018   
    P=N/A,  N=10, Recruiting, 
    Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Trial completion, Trial completion date, Trial primary completion date:  Long-term Treatment of Scalp Psoriasis With Xamiol (clinicaltrials.gov) -  Apr 4, 2018   
    P4,  N=951, Completed, 
    Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018 | Trial primary completion date: Dec 2017 --> Mar 2018
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Enrollment closed:  Long-term Treatment of Scalp Psoriasis With Xamiol (clinicaltrials.gov) -  Aug 22, 2017   
    P4,  N=950, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018 | Trial primary completion date: Dec 2017 --> Mar 2018 Recruiting --> Active, not recruiting
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Trial primary completion date:  Long-term Treatment of Scalp Psoriasis With Xamiol (clinicaltrials.gov) -  Jun 26, 2017   
    P4,  N=900, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: May 2017 --> Dec 2017
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Trial completion, Trial primary completion date:  Actinic Keratosis Study (clinicaltrials.gov) -  May 19, 2016   
    P0,  N=132, Completed, 
    Trial primary completion date: May 2017 --> Dec 2017 Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Mar 2015
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Enrollment change, Trial termination, Trial primary completion date:  Molecular Effects of Topical Calcipotriene on Morphea (clinicaltrials.gov) -  May 3, 2016   
    P=N/A,  N=2, Terminated, 
    Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Mar 2015 N=20 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Apr 2016; Accrual incomplete/Investigator left institution
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Enrollment open:  Long-term Treatment of Scalp Psoriasis With Xamiol (clinicaltrials.gov) -  Nov 8, 2015   
    P4,  N=900, Recruiting, 
    N=20 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Apr 2016; Accrual incomplete/Investigator left institution Not yet recruiting --> Recruiting
  • ||||||||||  C-82 Topical Gel, 1% / PRISM Pharma
    Trial completion:  Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test (clinicaltrials.gov) -  Oct 20, 2015   
    P1/2,  N=14, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed
  • ||||||||||  C-82 Topical Gel, 1% / PRISM Pharma
    Enrollment open:  Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test (clinicaltrials.gov) -  Jul 1, 2015   
    P1/2,  N=15, Recruiting, 
    Recruiting --> Completed Not yet recruiting --> Recruiting
  • ||||||||||  pefcalcitol (M 518101) / Maruho
    Enrollment closed, Trial primary completion date:  Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients (clinicaltrials.gov) -  Sep 4, 2014   
    P3,  N=725, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Trial completion, Trial primary completion date:  SHP-141C in Plaque Type Psoriasis (clinicaltrials.gov) -  Jul 12, 2014   
    P1,  N=14, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014 Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> Nov 2012
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Enrollment closed:  "Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy" (clinicaltrials.gov) -  Oct 17, 2013   
    P2/3,  N=54, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> Nov 2012 Recruiting --> Active, not recruiting
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Enrollment closed:  SHP-141C in Plaque Type Psoriasis (clinicaltrials.gov) -  Feb 5, 2013   
    P1,  N=14, Active, not recruiting, 
    Recruiting --> Completed Not yet recruiting --> Active, not recruiting
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Trial initiation date:  "Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy" (clinicaltrials.gov) -  Jan 23, 2013   
    P2/3,  N=54, Active, not recruiting, 
    Not yet recruiting --> Active, not recruiting Initiation date: Oct 2012 --> Feb 2013
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    New P1 trial:  SHP-141C in Plaque Type Psoriasis (clinicaltrials.gov) -  Jul 18, 2012   
    P1,  N=14, Active, not recruiting, 
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Trial completion:  LEO 90105 Ointment in Japanese Subjects With Psoriasis (clinicaltrials.gov) -  Apr 29, 2012   
    P3,  N=677, Completed, 
    Recruiting --> Completed Recruiting --> Completed